Please use this identifier to cite or link to this item:
Title: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Filiation: Hospital Universitario 12 de Octubre
Issue Date: 5-Apr-2018
Publisher: New England Journal of Medicine
Citation: N Engl J Med. 2018 Apr;(378)14:1277-1290
Abstract: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
PMID: 29562145
Rights: info:eu-repo/semantics/openAccess
ISSN: 0028-4793
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
29562145.pdf403.1 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.